Global Gastric Cancer Drugs Market Size study with COVID-19 impact, by Route of Administration (Oral. Parenteral), by Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), by Molecule Type (Small Molecule, Biologics) and Regional Forecasts 2020-2026

  • Product Code:
    RP-ID-10324780
  • Published Date:
    1 Jun 2020
  • Region:
    Global
  • Pages:
    200
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-14

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Global Gastric Cancer Drugs Market is valued approximately USD 3.0 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 15.5% over the forecast period 2020-2026. Gastric cancer, also known as stomach cancer, is characterized by an intensification of cancerous cells within the lining of the stomach. This type of cancer is usually complex to identify because most people normally do not show symptoms at the earlier stages. While gastric cancer is quite rare as compared to other forms of cancer. There are some other factors of gastric cancer that include certain diseases and conditions such as lymphoma, tumors in other parts of the digestive system, stomach polyps and many more. For these reasons, a number of chemo drugs are used to treat gastric cancer, including: 5-FU (fluorouracil), frequently given along with leucovorin (folinic acid), Capecitabine (Xeloda), Carboplatin, and many more. High incidences of gastric cancer among people owing to unhealthy diet, increasing number of obesity cases and growing elderly population are the few factors responsible for high CAGR of the market over the forecast period. For instance, the National Cancer Institute (NCI) estimated that around 28,000 new cases of stomach cancer in 2017. Also, NCI estimates that stomach cancer is about 1.7 percent of new cancer cases in the United States. Similarly, as per the GLOBOCAN 2018, the number of prevalence cases of stomach cancer in Asia was around 769,728 and is projected to grow to almost 947,186 by 2025. Although gastric cancer therapies can increase the chances of survival for patients living with gastric cancer. This, in turn, is expected to accelerate the demand of Gastric Cancer Drugs around the world. Amidst the COVID-19 outbreak across the world, the pharma industry is more concerned on the development of COVID-19 vaccine, thus, R&D efforts for gastric cancer drugs is substantially decline. Though, the demand for gastric cancer drugs is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at significant rate in the upcoming years. However, high cost of cancer therapy and stringent regulations and policies for approval of the drugs are some other factor limiting the market growth over the forecast period of 2020-2026.

The regional analysis of global Gastric Cancer Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia-Pacific is the leading/significant region across the world in terms of market share owing to rising number of gastric cancer cases, introduction of novel therapies for metastatic gastric cancer, and the presence of larger consumer base seeking treatment, particularly in China, India and Japan. Whereas, North America is anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing R&D efforts by pharmaceuticals for gastric cancer drugs and supportive government policies in the region.

Major market player included in this report are:
Amgen
AROG Pharmaceuticals
Ipsen Biopharmaceuticals
Array Biopharma
Taiho Oncology
AstraZeneca
ARIAD Pharmaceuticals
Eli Lilly
Galena Biopharma
ASLAN Pharmaceuticals

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Route of Administration:
Oral
Parenteral

By Lines of Chemotherapy:
First-line Chemotherapy
Second-line Chemotherapy

By Molecule Type:
Small Molecule
Biologics

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017, 2018
Base year – 2019
Forecast period – 2020 to 2026

Target Audience of the Global Gastric Cancer Drugs Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
TABLE OF CONTENTS
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2026 (USD Billion)
1.2.1. Gastric Cancer Drugs Market, by Region, 2018-2026 (USD Billion)
1.2.2. Gastric Cancer Drugs Market, by Route of Administration, 2018-2026 (USD Billion)
1.2.3. Gastric Cancer Drugs Market, by Lines of Chemotherapy, 2018-2026 (USD Billion)
1.2.4. Gastric Cancer Drugs Market, by Molecule Type, 2018-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Gastric Cancer Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Gastric Cancer Drugs Market Dynamics
3.1. Gastric Cancer Drugs Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Gastric Cancer Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Gastric Cancer Drugs Market, by Route of Administration
5.1. Market Snapshot
5.2. Global Gastric Cancer Drugs Market by Route of Administration, Performance - Potential Analysis
5.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Route of Administration 2016-2026 (USD Billion)
5.4. Gastric Cancer Drugs Market, Sub Segment Analysis
5.4.1. Oral
5.4.2. Parenteral
Chapter 6. Global Gastric Cancer Drugs Market, by Lines of Chemotherapy
6.1. Market Snapshot
6.2. Global Gastric Cancer Drugs Market by Lines of Chemotherapy, Performance - Potential Analysis
6.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Lines of Chemotherapy 2016-2026 (USD Billion)
6.4. Gastric Cancer Drugs Market, Sub Segment Analysis
6.4.1. First-line Chemotherapy
6.4.2. Second-line Chemotherapy
Chapter 7. Global Gastric Cancer Drugs Market, by Molecule Type
7.1. Market Snapshot
7.2. Global Gastric Cancer Drugs Market by Molecule Type, Performance - Potential Analysis
7.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Molecule Type 2016-2026 (USD Billion)
7.4. Gastric Cancer Drugs Market, Sub Segment Analysis
7.4.1. Small Molecule
7.4.2. Biologics
Chapter 8. Global Gastric Cancer Drugs Market, Regional Analysis
8.1. Gastric Cancer Drugs Market, Regional Market Snapshot
8.2. North America Gastric Cancer Drugs Market
8.2.1. U.S. Gastric Cancer Drugs Market
8.2.1.1. Route of Administration breakdown estimates & forecasts, 2016-2026
8.2.1.2. Lines of Chemotherapy breakdown estimates & forecasts, 2016-2026
8.2.1.3. Molecule Type breakdown estimates & forecasts, 2016-2026
8.2.2. Canada Gastric Cancer Drugs Market
8.3. Europe Gastric Cancer Drugs Market Snapshot
8.3.1. U.K. Gastric Cancer Drugs Market
8.3.2. Germany Gastric Cancer Drugs Market
8.3.3. Rest of Europe Gastric Cancer Drugs Market
8.4. Asia-Pacific Gastric Cancer Drugs Market Snapshot
8.4.1. China Gastric Cancer Drugs Market
8.4.2. India Gastric Cancer Drugs Market
8.4.3. Japan Gastric Cancer Drugs Market
8.4.4. Rest of Asia Pacific Gastric Cancer Drugs Market
8.5. Latin America Gastric Cancer Drugs Market Snapshot
8.5.1. Brazil Gastric Cancer Drugs Market
8.5.2. Mexico Gastric Cancer Drugs Market
8.6. Rest of The World Gastric Cancer Drugs Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Amgen
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. AROG Pharmaceuticals
9.2.3. Ipsen Biopharmaceuticals
9.2.4. Array Biopharma
9.2.5. Taiho Oncology
9.2.6. AstraZeneca
9.2.7. ARIAD Pharmaceuticals
9.2.8. Eli Lilly
9.2.9. Galena Biopharma
9.2.10. ASLAN Pharmaceuticals
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research AssumptionList of Tables
TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL GASTRIC CANCER DRUGS MARKET
TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL GASTRIC CANCER DRUGS MARKET
TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY ROUTE OF ADMINISTRATION 2016-2026 (USD BILLION)
TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY LINES OF CHEMOTHERAPY 2016-2026 (USD BILLION)
TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY MOLECULE TYPE 2016-2026 (USD BILLION)
TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 16. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 17. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 18. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 19. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 20. U.S. GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 21. U.S. GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 22. U.S. GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 23. CANADA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 24. CANADA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 25. CANADA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 26. UK GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 27. UK GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 28. UK GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 29. GERMANY GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 30. GERMANY GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 31. GERMANY GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 32. ROE GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 33. ROE GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 34. ROE GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 35. CHINA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 36. CHINA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 37. CHINA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 38. INDIA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 39. INDIA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 40. INDIA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 41. JAPAN GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 42. JAPAN GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 43. JAPAN GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 44. ROAPAC GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 45. ROAPAC GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 46. ROAPAC GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 47. BRAZIL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 48. BRAZIL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 49. BRAZIL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 50. MEXICO GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 51. MEXICO GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 52. MEXICO GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 53. ROLA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 54. ROLA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 55. ROLA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 56. ROW GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 57. ROW GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 58. ROW GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)List of Figures
FIG 1. GLOBAL GASTRIC CANCER DRUGS MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL GASTRIC CANCER DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL GASTRIC CANCER DRUGS MARKET, KEY TRENDS 2019
FIG 5. GLOBAL GASTRIC CANCER DRUGS MARKET, GROWTH PROSPECTS 2020-2026
FIG 6. GLOBAL GASTRIC CANCER DRUGS MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL GASTRIC CANCER DRUGS MARKET, PEST ANALYSIS
FIG 8. GLOBAL GASTRIC CANCER DRUGS MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 10. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 11. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 12. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 13. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 14. GLOBAL GASTRIC CANCER DRUGS MARKET, REGIONAL SNAPSHOT 2016 & 2026
FIG 15. NORTH AMERICA GASTRIC CANCER DRUGS MARKET 2016 & 2026 (USD BILLION)
FIG 16. EUROPE GASTRIC CANCER DRUGS MARKET 2016 & 2026 (USD BILLION)
FIG 17. ASIA PACIFIC GASTRIC CANCER DRUGS MARKET 2016 & 2026 (USD BILLION)
FIG 18. LATIN AMERICA GASTRIC CANCER DRUGS MARKET 2016 & 2026 (USD BILLION)
FIG 19. GLOBAL GASTRIC CANCER DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Amgen
AROG Pharmaceuticals
Ipsen Biopharmaceuticals
Array Biopharma
Taiho Oncology
AstraZeneca
ARIAD Pharmaceuticals
Eli Lilly
Galena Biopharma
ASLAN Pharmaceuticals
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports